London--(Marketwire - September 24, 2007) -
Curidium Medica plc ("Curidium" or the "Company")
CURIDIUM TO PRESENT AT UBS 2007 GLOBAL LIFE SCIENCES CONFERENCE
-Presentation to be Webcast Live -
London, UK, 24 September 2007, Curidium Medica plc, (LSE: CUR) the personalized
medicine company focused on bringing the right drug to the right patient, today
announced that it will be presenting at the 2007 UBS Global Life Sciences
Conferences in New York, New York, USA. Gosse B. Bruinsma, Executive Chairman,
will be presenting the current status of the Company and its strategic business
objectives. The presentation is scheduled at 1:00 pm local time on Thursday, 27
September 2007 in the Grand Hyatt Hotel. The presentation will be webcast and
accessible remotely by persons wishing to follow the presentation live and will
be archived for 30 days on the Company's website; for access please visit:
www.ibb.ubs.com.
For further information, please contact:
Gosse B. Bruinsma, M.D. +31 (0) 629 046 397
Chairman, Curidium Medica plc
Anne Bruinvels +44 (0) 20 7554 8790
Chief Executive Officer, Curidium Medica plc
Rob Smith +44 (0) 20 7554 8793
Finance Director, Curidium Medica plc
Rhodri Cruwys / Romil Patel +44 (0) 20 7448 4400
Blue Oar Securities Plc
Billy Clegg / Edward Westropp / Annie Evangeli + 44 (0)20 7831 3113
Financial Dynamics
Notes to Editors
Curidium Medica
Curidium is a personalized medicine company identifying targeted medicines and
companion diagnostics to treat patients more effectively.
Curidium's initial focus on diseases of the Central Nervous System has resulted
in the identification of a blood diagnostic test, PsychINDx™, which classifies
patients with schizophrenia/bipolar disorder into four subgroups. PsychINDx™
may have the potential to improve the treatment of patients with schizophrenia/
bipolar disorder.
Many chronic human diseases are heterogeneous and their patient populations
consist of mixed subgroups. Through the use of its proprietary analysis tool,
Homomatrix®, Curidium aims to reveal different patient subgroups characterized
by distinct underlying disease mechanisms potentially leading to the
identification of:
1. Diagnostics for better identification and treatment within heterogeneous
disease populations.
2. Improved therapies identified through novel drug targets.
3. Personalized medicines using companion diagnostics and targeted treatments.
Curidium aims to continue to use this approach to improve patient treatments in
a variety of therapeutic areas. Further information on Curidium can be found at
the Company's website:
www.curidium.com.
Curidium Medica plc (c) 2002-2007. All rights reserved.
Hamilton House, Mabledon Place, London WC1H 9BB, United Kingdom.
Email: info@curidium.com Tel.: +44 (0)20 7554 8790,
Fax: +44 (0)20 7554 8791
This information is provided by RNS
The company news service from the London Stock Exchange